<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557619</url>
  </required_header>
  <id_info>
    <org_study_id>M16-185</org_study_id>
    <nct_id>NCT03557619</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies</brief_title>
  <official_title>A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of&#xD;
      ethinyl estradiol and levonorgestrel in female participants with different hematological&#xD;
      malignancies. Upon completion of this study, participants receiving clinical benefit in the&#xD;
      opinion of the investigator and without any clinically significant evidence of disease&#xD;
      progression with no access to venetoclax (not approved for the treated indication) may&#xD;
      continue receiving venetoclax at the discretion of the investigator in a separate extension&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of Venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of (ethinyl estradiol) EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of Venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of Venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>AUC from time 0 extrapolated to infinite time (AUCinf) of EE/Levonorgestrel.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol/levonorgestrel</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <other_name>Levora</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have relapsed or refractory non-Hodgkin's lymphoma (NHL).&#xD;
&#xD;
          -  Participant must have histologically documented diagnosis of one of the following NHL&#xD;
             subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL),&#xD;
             lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma&#xD;
             (MZL), T-cell prolymphocytic lymphoma (T-PLL), Waldenstr√∂m's macroglobulinemia (WM)&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or&#xD;
             equal to two.&#xD;
&#xD;
          -  Must have adequate bone marrow, coagulation, renal and hepatic function as described&#xD;
             in the protocol.&#xD;
&#xD;
          -  A female of non-childbearing potential as described in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of currently active, clinically significant cardiovascular disease.&#xD;
&#xD;
          -  If the participant has had prior stem cell transplantation, it must have been more&#xD;
             than 100 days prior to start of study drug, with no graft versus host disease, and no&#xD;
             immunosuppression therapy.&#xD;
&#xD;
          -  Evidence of transformation of the lymphoma immediately prior to study entry.&#xD;
&#xD;
          -  Evidence of central nervous system involvement by lymphoma.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 209090</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center /ID# 169097</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research /ID# 207039</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre /ID# 225248</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre-East Melbourne /ID# 225247</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com</url>
    <description>Related info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Hematologic Malignancies, venetoclax</keyword>
  <keyword>ethinyl estradiol</keyword>
  <keyword>relapsed or refractory non-Hodgkin's lymphoma</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

